text_1: Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.
text_2: CONCLUSIONS This meta-analysis, including the entire large-scale trial experience of intravenous platelet GP IIb/IIIa inhibitors for the medical management of non-ST-segment-elevation ACS, shows that these agents may significantly reduce mortality at 30 days in diabetic patients.